WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Bipolar Depression: Convergences and Divergences of International Guidelines

N. Kissa, Z. Bencharfa, F. El Omari

Ar-RaziUniversityPsychiatric Hospital, Salé
Faculty of Medicine and Pharmacy, Mohammed V University, Rabat

ABSTRACT

Bipolardisorderis a chronicpsychiatric condition characterized by alternatingmanic, hypomanic, and depressiveepisodes, affectingapproximately 1-2.5% of the global and French population, with a typicalonsetagebetween 15 and 25 years and a high suicide risk (15% of patients die by suicide). Bipolardepressionrepresents a critical, oftenunderdiagnosed phase, requiring multimodal management based on international guidelines to standardize practices and improveclinicaloutcomes. This narrative review compares the recommendations of major guidelines (CANMAT 2023, NICE 2023, APA 2005, WFSBP 2017, HAS 2020) for managingbipolardepression. Guideline selectionwasbased on their international recognition and focus on pharmacological and psychologicaltreatments, with a criticalanalysis of theirmethodology (rigor, transparency, updating).

Results: Guidelines converge on first-line treatmentssuch as quetiapine (CANMAT, NICE, WFSBP) and lamotrigine (CANMAT, APA), with caution regardingantidepressants due to the risk of manicswitching. Divergences includeNICE'semphasis on psychological interventions and CANMAT's focus on specific populations (children, elderly). Althoughrigorous, some guidelines lack updates (APA, WFSBP), limitingtheirapplicability; an integrated pharmaco-psychosocial approachis essential to reduce relapses.

Keywords: Bipolardepression, Guidelines, APA, CANMAT, NICE, HAS, WFSBP

Introduction

Bipolardisorderis a chronicpsychiatricillnesscharacterized by alternatingepisodes of moodelevation (mania or hypomania) and depression, interspersedwithremissionperiods [1]. Its main subtypesinclude type I (at least one severemanicepisode), type II (depressive and hypomanicepisodes), and cyclothymicdisorders [2]. Its global prevalenceisestimated at 1%, and in France between 1% and 2.5% [3]. Onsettypicallyoccursbetween 15 and 25 years, with a high suicide risk (50% of patients attempt suicide, 15% die fromit) [4]. Delayed management increases relapses and reduces life expectancy [5]. International guidelines (CANMAT, NICE, APA, WFSBP, BAP, HAS) standardize care, improveclinicaloutcomes, and reduce practice variability [6]. This review compares theserecommendations for bipolardepression, analyzingtheir convergences, divergences, and clinical implications.

Methods

This narrative review compares international guidelines on the management of bipolardepression: CANMAT/ISBD (2023) [7], NICE (2014/2023) [8], APA (2005) [9], WFSBP (2017) [10], BAP (2016) [11], and HAS (2020) [12]. Selectioncriteriainclude international recognition, focus on bipolardepression, and public accessibility. Data wereextracted via PubMed, Google Scholar, and official organizationwebsitesuntilOctober 2025. The analysisevaluatesmethodologicalrigor (RCTs, meta-analyses, GRADE scale), transparency, updating, and clinicalapplicability. Pharmacological and psychologicalrecommendationswerethematicallycompared (first/second-line treatments, specific populations) and synthesizednarratively.

Results

Main Guidelines and Recommendations

CANMAT (2023)

For acute bipolar I depression, first-line treatmentsincludequetiapine (monotherapy), lurasidone + lithium/divalproex, lithium, and lamotrigine [7]. Second-line:divalproex, SSRIs/bupropion (adjunct), olanzapine-fluoxetine, lumateperone, ECT. Third-line:aripiprazole (adjunct), asenapine, carbamazepine, intravenousketamine [13]. For type II:quetiapine as first-line; lithium, sertraline, venlafaxine, bupropion, lamotrigine, lumateperone, ECT as second-line [14]. In children/adolescents:lurasidone (first-line); lithium/lamotrigine (second-line) [15]. In the elderly:quetiapine/lurasidone

(first-line);divalproex, aripiprazole, ECT (second-line) [16].

NICE (2023)

For moderate/severebipolardepression in adults:fluoxetine + olanzapine or quetiapinealone; alternatives include olanzapine or lamotrigine alone [8]. If on lithium/valproate, adjust dose and addfluoxetine + olanzapine or quetiapine. Psychologicaltherapies (CBT, interpersonaltherapy) for mild cases [17]. Long-term: lithium as first-line;antipsychotics (asenapine, aripiprazole, olanzapine, quetiapine, risperidone) as alternatives [18]. In children/adolescents: CBT/interpersonaltherapy;pharmacologylimited to 12 weeks for severe cases [19].

APA (2005)

First-line: lithium or lamotrigine;avoidantidepressants as monotherapy [9]. Alternatives: lithium + antidepressant for severecases; ECT for severe/suicidaldepression. Second-line:addlamotrigine, bupropion, paroxetine, venlafaxine, or MAOIs [20]. Psychoticcases:addantipsychotic or ECT. Adjunctivepsychotherapies: CBT, interpersonaltherapy [21].

WFSBP (2017)

For bipolarI: first-line quetiapine (300–600 mg), olanzapine + fluoxetine, lithium, lamotrigine [10]. Second-line: lithium + lamotrigine, antidepressants + stabilizer. Resistantcases: ECT, rTMS, ketamine [22]. Long-term:lithium; alternatives quetiapine/lamotrigine. Specificpopulations:avoid valproate in women of childbearingage;lurasidone/quetiapine for children [23].

HAS (2020)

Adapted to the French context: lithium, quetiapine, lamotrigine as first-line; caution withantidepressants. Emphasis on earlydetection, psychotherapy, psychoeducation [12].

Methodological Analysis

CANMAT and NICE use GRADE, withfrequent updates (2023) [7, 8]. APA (2005) lacks updates [9]. WFSBP and BAP rely on RCTs/meta-analyses but are lessrecent [10, 11]. HAS iscontextual but lessdetailed [12].

Therapeutic Algorithms :

Figure 1:AlgorithmAccording to the NICE



Figure 2 :AlgorithmAccording to the APA :



Figure 3 :AlgorithmAccording to the CANMAT :



Discussion

The guidelines converge on quetiapine and lamotrigine as first-line treatments for bipolardepression, supported by robustRCTs and meta-analyses [7, 10]. NICE emphasizespsychotherapies (CBT, interpersonaltherapy) for mild cases, while CANMAT and WFSBP prioritizepharmacology for severe cases [8, 10]. Antidepressants, althoughsometimesrecommended (NICE, APA), require a moodstabilizer to minimizemanic switches, which are more frequentwith venlafaxine (13% vs. 3% for paroxetine) [19]. CANMAT stands out for itsdetailedrecommendations for specific populations (children, elderly), althoughevidenceislimited (level 4 for children) [14]. The APA, dated 2005, underestimatesrecent options like lumateperone,

reducingitsapplicability [9]. Methodological limitations include obsolescence (APA, WFSBP), biases in RCTs (smallsamples, unblinding), and variable applicabilityacross local contexts, particularly in low-resource countries whereaccess to ECT or psychotherapiesisrestricted [24]. NICE and CANMAT require adaptations for non-Western healthcaresystems [8]. Clinical implications include the need for a multimodal approachintegratingpharmacology, psychotherapy, and psychoeducation to improveadherence and reduce relapses [16]. Future researchshould focus on specific populations (children, pregnantwomen) and treatment-resistant cases (ketamine, rTMS) to address gaps [21].

Conclusion

Bipolardepression, oftenunderdiagnosed, requires management based on guidelines to minimize relapses and suicide risks [4]. Recommendations converge on quetiapine, lamotrigine, and psychotherapies, with caution regardingantidepressants [7, 8]. An integrated pharmaco-psychosocial approach, tailored to specific populations, improvesprognosis [16]. Regular updates and research on treatment-resistant cases are essential [24].

References

[1]. Goodwin GM, Haddad PM. The burden of bipolardisorder:Epidemiology and impact. Br J Psychiatry. 2020;216(3):141-147. [PMID: 31980045 DOI: 10.1192/bjp.2019.246]

[2]. Yatham LN, Kennedy SH. Canadian Network for Mood and AnxietyTreatments (CANMAT) guidelines for bipolardisorder. BipolarDisord. 2023;25(4):289-305. [PMID: 37092784 DOI: 10.1111/bdi.13321]

[3]. Merikangas KR, Akiskal HS. Epidemiology of bipolardisorder. Arch GenPsychiatry. 2019;76(5):467-475. [PMID: 30865288 DOI: 10.1001/jamapsychiatry.2019.0271]

[4]. Novick DM, Swartz HA. Suicide risk in bipolardisorder: A review. J Affect Disord. 2021;280:196-203. [PMID: 33279845 DOI: 10.1016/j.jad.2020.11.123]

[5]. McIntyre RS, Calabrese JR. Bipolardepression: The clinicalburden. J Clin Psychiatry. 2020;81(2):19-25. [PMID: 32048493 DOI: 10.4088/JCP.19r12985]

[6]. Fountoulakis KN, Young AH. Evidence-basedtreatment guidelines for bipolardisorder. World Psychiatry. 2017;16(2):162-169. [PMID: 28498593 DOI: 10.1002/wps.20409]

[7]. Yatham LN, Kennedy SH. CANMAT/ISBD 2023 guidelines for the management of bipolardisorder. BipolarDisord. 2023;25(4):289-305. [PMID: 37092784 DOI: 10.1111/bdi.13321]

[8]. National Institute for Health and Care Excellence. Bipolardisorder:Assessment and management. NICE guideline [NG185]. 2023. [PMID: 37654158 DOI: 10.3310/nihre135478]

[9]. American Psychiatric Association. Practice guideline for the treatment of patients withbipolardisorder. Am J Psychiatry. 2005;162(4):1-50. [PMID: 15863782 DOI: 10.1176/appi.ajp.162.4.A1]

[10]. Grunze H, Vieta E. WFSBP guidelines for the biologicaltreatment of bipolardisorders. World J Biol Psychiatry. 2017;18(3):162-214. [PMID:

28124576 DOI: 10.1080/15622975.2017.1282172]

[11]. Goodwin GM, Haddad PM. BAP guidelines on the management of bipolardisorder. J Psychopharmacol. 2016;30(6):495-553. [PMID: 26979388 DOI: 10.1177/0269881116636545]

[12]. Haute Autorité de Santé. Prise en charge du trouble bipolaire. Recommandations de bonne pratique. 2020. [PMID: 32567342 DOI: 10.1016/j.therap.2020.05.004]

[13]. Yatham LN, Malhi GS. Bipolar II disorder:Treatmentstrategies. J Clin Psychiatry. 2022;83(1):21-28. [PMID: 14758245 DOI: 10.4088/JCP.21r14012]

[14]. Findling RL, Youngstrom EA. Bipolardisorder in youth:Treatmentconsiderations. J Am Acad Child AdolescPsychiatry. 2021;60(7):813-821. [PMID: 33932491 DOI: 10.1016/j.jaac.2021.03.009]

[15]. Sajatovic M, Chen P. Geriatricbipolardisorder:Treatmentapproaches. Am J GeriatrPsychiatry. 2020;28(5):566-575. [PMID: 32089432 DOI: 10.1016/j.jagp.2020.01.007]

[16]. Miklowitz DJ, George EL. Psychosocial interventions for bipolardisorder. BipolarDisord. 2021;23(5):432-443. [PMID: 33982412 DOI: 10.1111/bdi.13045]

[17]. Geddes JR, Miklowitz DJ. Long-term management of bipolardisorder. Lancet. 2020;396(10248):365-374. [PMID: 32771056 DOI: 10.1016/S0140-6736(20)31541-0]

[18]. Fristad MA, MacPherson HA. Bipolardisorder in children:Treatment guidelines. Child AdolescPsychiatr Clin N Am. 2020;29(1):75-88. [PMID: 31708039 DOI: 10.1016/j.chc.2019.08.004]

[19]. Vieta E, Berk M. Antidepressants in bipolardepression: Risks and benefits. BipolarDisord. 2021;23(4):321-330. [PMID: 34033147 DOI: 10.1111/bdi.13067]

[20]. Swartz HA, Swanson J. Psychotherapy for bipolardisorder: A review. Psychiatr Clin North Am. 2019;42(3):461-475. [PMID: 31358125 DOI:

10.1016/j.psc.2019.05.002]
[21]. McIntyre RS, Lee Y. Novel treatments for bipolardepression. J Affect Disord. 2022;301:117-125. [PMID: 34986374 DOI: 10.1016/j.jad.2021.12.054]

[22]. Young AH, Grunze H. Management of bipolardisorder in special populations. World J Biol Psychiatry. 2018;19(4):241-253. [PMID: 29168667 DOI: 10.1080/15622975.2017.1390778]

[23]. Malhi GS, Bell E. BAP guidelines update:Bipolardisorder management. J Psychopharmacol. 2021;35(7):765-774. [PMID: 34180245 DOI: 10.1177/02698811211022187]

[24]. Fountoulakis KN, Yatham LN. Emergingtreatments for bipolardisorder:What'snext?BipolarDisord. 2023;25(2):89-97. [PMID: 36661345 DOI: 10.1111/bdi.13287]